In Focus: Myopia management treatment updates

Results of the three-year clinical trial results of Essilor’s Stellest spectacle lens were presented at the International Myopia Conference (IMC) 2022 in Rotterdam, recently.

The results showed lenses continued to exhibit strong efficacy in slowing myopia progression and axial elongation in the third year of the trial, which was conducted at the Eye Hospital of Wenzhou Medical University in Wenzhou, China. A total of 151 children from the first two years of the study were switched to spectacle lenses with highly aspherical lenslets (HAL), while a new set of 56 children were recruited and wore single vision lenses.

Essilor said Stellest saved more than one dioptre of myopia on average over three years when compared to single vision lens wearers in the first 24 months of use and the new control group of 56 children recruited for the third year. This demonstrated ‘conclusive evidence that the lenses remained effective slowing down myopia progression in children in the third year of use.’ Children who wore the lenses for 12 hours or over each day also saw a marked increase in myopia management efficacy.